Table 1.
Baseline characteristics of patients by serum uric acid (SUA) quartiles.
| Quartiles of serum uric acid (n = 1,534) | ||||||
|---|---|---|---|---|---|---|
| Variables | Total | Q1 | Q2 | Q3 | Q4 | P-value |
| Number of subjects | 1,534 | 389 | 381 | 384 | 380 | |
| SUA, μmol/L | 397.70 ± 87.85 | 296.37 ± 38.86 | 366.34 ± 24.65 | 418.93 ± 26.26 | 511.40 ± 58.49 | <0.001 |
| Male, N (%) | 775 (50.5) | 196 (50.4) | 193 (50.7) | 193 (50.3) | 193 (50.8) | 0.999 |
| Age, years | 60.11 ± 13.33 | 60.70 ± 13.98 | 60.02 ± 13.36 | 60.63 ± 13.453 | 59.09 ± 12.47 | 0.307 |
| Smoking, N (%) | 440 (28.7) | 108 (27.8) | 98 (25.7) | 117 (30.5) | 117 (30.8) | 0.518 |
| Alcohol use, N (%) | 362 (23.6) | 87 (22.4) | 82 (21.5) | 95 (24.7) | 98 (25.8) | 0.798 |
| SBP, mm Hg | 130.45 ± 9.31 | 130.40 ± 9.45 | 129.74 ± 9.10 | 130.29 ± 9.69 | 131.33 ± 8.93 | 0.125 |
| DBP, mm Hg | 80.79 ± 9.11 | 80.02 ± 9.35 | 80.71 ± 8.96 | 81.51 ± 9.27 | 80.92 ± 8.79 | 0.153 |
| Diabetes, N (%) | 424 (27.6) | 92 (23.7) | 109 (28.6) | 108 (28.1) | 115 (30.3) | 0.201 |
| Dyslipidemia, N (%) | 1,219 (79.7) | 296 (76.7) | 290 (76.3) | 321 (83.6) | 312 (82.1) | 0.020 |
| Statins use, N (%) | 1,077 (70.2) | 251 (64.5) | 267 (70.1) | 290 (75.5) | 269 (70.8) | 0.010 |
| TC, mg/dL | 193.17 ± 40.57 | 193.25 ± 40.64 | 193.47 ± 39.70 | 193.17 ± 41.66 | 192.80 ± 40.39 | 0.997 |
| TG, mg/dL | 163.20 ± 131.46 | 151.90 ± 146.58 | 146.6 ± 92.16 | 161.29 ± 113.66 | 193.28 ± 158.12 | <0.001 |
| HDL-c, mg/dL | 47.65 ± 10.98 | 49.451 ± 11.43 | 47.806 ± 10.722 | 47.26 ± 10.89 | 46.04 ± 10.63 | <0.001 |
| LDL-c, mg/dL | 107.88 ± 27.30 | 107.07 ± 26.94 | 108.59 ± 27.16 | 108.38 ± 27.80 | 107.49 ± 27.36 | 0.849 |
| Creatinine, μmol//L | 71.09 ± 41.59 | 66.69 ± 38.79 | 67.10 ± 18.35 | 71.87 ± 19.28 | 79.09 ± 41.59 | <0.001 |
| eGFR (mL/min/1.73 m2) | 90.36 ± 21.00 | 94.87 ± 21.43 | 93.11 ± 18.91 | 88.51 ± 20.00 | 84.86 ± 22.07 | <0.001 |
| Diuretics use, N (%) | 474 (30.9) | 101 (26.0) | 111 (29.1) | 128 (33.3) | 134 (35.3) | 0.024 |
| CCB use, N (%) | 1,402 (91.4) | 354 (91.0) | 353 (92.7) | 346 (90.1) | 349 (91.8) | 0.626 |
| ACEI/ARB use, N (%) | 501 (32.7) | 116 (29.8) | 101 (26.5) | 138 (35.9) | 146 (38.4) | 0.001 |
| β-blockers use, N (%) | 758 (49.4) | 174 (44.7) | 183 (48.0) | 192 (50.0) | 209 (55.0) | 0.037 |
Data were presented as mean ± SD for continuous variable and number (percentage) for category variables. The quartiles of SUA concentration were calculated separately for men and women. The cut-off of SUA levels in men was ≤356.00, 356.01–412.00, 412.01–467.00 and ≥467.01 μmol/L. The cut-off of SUA levels in women was ≤ 320.00, 320.01–369.00, 369.01–433.00 and ≥433.01 μmol/L. SUA, serum uric acid; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate; CCB, Calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.